Linkedin
Sign in
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Type here...
Search
Home
About
Editor’s Corner
Contribute
Contact Us
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
Solutions & Pricing
Partner
Instagram
Linkedin
Twitter
Subscribe
Subscribe
Saturday, April 25, 2026
24.9
C
Bengaluru
Home
About
Editor’s Corner
Contribute
Contact Us
My account
Get into your account.
Login
Register
type here...
Search
Facebook
Linkedin
Twitter
Youtube
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
From Overuse to Overreaction: Recalibrating India’s C-Section Debate
0
India’s caesarean section debate is drifting toward polarisation. On one...
Indian Pharma Market Through a Game Theory Lens
0
A Salil Kallianpur Blog Explosive value growth, limited volume growth –...
Time for Indian Pharma to Dive into Digital
0
When was the first time that we heard the...
Customer Engagement and Experience are the New Differentiators
0
At the IDMA Marketing and Sales Conference in Mumbai...
When Influence Meets Accountability: Why India Wants Wellness Gurus to Show Their Credentials
0
India’s wellness economy is booming—nutraceuticals, supplements, and alternative therapies...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Marketing
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Policies/Sales
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Strategy
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Subscribe
Thought Leadership
Healthcare C-Suite Movements
Digital in Pharma
Events
FFE+CEO RT
BrandStorm
Solutions & Pricing
Partner
Hot topics
Eli Lilly’s $6.5 Billion Houston Bet: A Strategic Play in U.S. Manufacturing, Policy, and the Next Wave of Obesity Treatment
0
When Eli Lilly announced plans to build a $6.5...
Prabhir Jha: Digital is not just another technology, it is a mind-set
0
DigiStorm 2018 was held on 11 September at the...
Not Digital Solutions alone, but Business Solutions that add Value to Customers delivered via Digital Platforms
0
Yesterday I received a WhatsApp from a famous shoe...
IMS Health Market Reflection Report for August 2016
0
The Indian Pharmaceutical Market (IPM) was valued at Rs. 10,426 crores in the month of August 2016 clocking a strong 18% growth over same period last year (SPLY). This was the second consecutive month where the IPM crossed the 10,000 crore mark.
Can Indian Doctors and Patients Trust Generics Over Branded Generics? ...
0
The ongoing debate around branded versus generic medicines in...
Facebook
Linkedin
Twitter
Youtube
Healthcare Trends
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Marketing
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Policies/Sales
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Strategy
Is Pharma M&A Slowing Down Amidst Geopolitical Friction?
0
The pharmaceutical industry stands at a critical juncture in...
Will the GLP Battle Now Shift from Injectable to Oral?
0
In India’s million-strong retail pharmacy universe, oral weight-loss pills...
The Semaglutide Paradox: Anatomy of a High-Stakes Commodity Trap
0
The Semaglutide Shift: From Blockbuster to Commodity Why the $50...
Cytotoxics to Cell Therapy: A 40-Year Review of Indian Oncology Strategy
0
In 1989, oncology in India was not a business...
Ritesh Desai has joined Standard Chartered India as Executive Director
0
Ritesh Desai has joined Standard Chartered India as Executive...
Subscribe
Screen Shot 2015-03-08 at 8.14.58 PM